LATEST NEWS
NeuroDelta presents at EPIC Biotechnology Conference... More here

applications

NeuroDelta has identified a novel protein modification (phosphorylated amyloid-β) linked to Alzheimer s pathology. The company has also identified compounds that can be used both to detect protein interactions with amyloid-β and to develop model compounds. These model compounds will be examined to see if they can prevent formation of the modified protein, or prevent its subsequent actions, and will form the basis for development of therapeutic agents. Such agents would potentially halt the further progression of Alzheimer's Disease. NeuroDelta will also look into the development of agents that measure the degree of protein modification and will serve as the basis of a diagnostic detection system.

Research is currently underway to characterise those therapeutic and diagnostic targets that can be commercially exploited. Though initial focus will be on compounds associated with Alzheimer's, long-term goals will be identifying targets for other Neurodegenerative diseases including Parkinson's, Amyotrophic Lateral Sclerosis and Stroke. All therapeutic or diagnostic agents identified and developed by NeuroDelta will be marketable to larger Biotechnology and Pharmaceutical Companies under patent protection.

At present, NeuroDelta hopes to address a significant proportion of the multi-billion dollar global market for AD, with a superior drug that completely halts progression of the disease. Regulatory requirements mean that delivering a full therapeutic to market can be achieved within 5-7 years.

The initial product is likely to be a diagnostic assay to measure the levels of modified protein. The ultimate intentions of NeuroDelta are to take therapeutic drug discovery to clinical trials, prior to out-licensing the downstream development to pharmaceutical, biotechnology and diagnostic companies.